Low-Dose Quadruple Antihypertensive Combination
- 1 February 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 49 (2), 272-275
- https://doi.org/10.1161/01.hyp.0000254479.66645.a3
Abstract
Increasingly combined antihypertensive agents are being used in practice to enhance control and improve compliance. To determine whether a capsule containing a quarter of the standard dose of 4 antihypertensive agents has greater efficacy than the standard dose of each individually, we prospectively randomized 108 untreated white hypertensive patients (55% male) aged 50±1 years (mean±SEM), with mean blood pressure 160±1/96±1 mm Hg. Patients received amlodipine (5 mg; n=22), atenolol (50 mg; n=20), bendroflumethiazide (2.5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks. Blood pressure was measured using a semiautomated device (Omron 705), and the reduction in mean arterial pressure with the combined preparation was compared with that of the individual components. Statistical analysis used ANOVA and Tukey-Kramer honestly significant difference for multiple comparisons. The reduction in mean arterial pressure with the combination (19±2 mm Hg) was significantly greater than that with individual agents amlodipine (10±2 mm Hg; P P P P P P =0.06) blood pressure was greater with the combination. More patients achieved a blood pressure of P <0.05). A low-dose combination of 4 agents representing 4 classes of standard antihypertensive agents was more efficacious than a standard single dose of each agent individually.Keywords
This publication has 12 references indexed in Scilit:
- Profit and loss analysis for an intensive care unit (ICU) in Japan: a tool for strategic managementBMC Health Services Research, 2006
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialThe Lancet, 2005
- Predictors of Adherence With Antihypertensive and Lipid-Lowering TherapyArchives of Internal Medicine, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialThe Lancet, 2004
- British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summaryBMJ, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Evidence From New Hypertension TrialsHypertension, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ, 2003
- Optimisation of antihypertensive treatment by crossover rotation of four major classesThe Lancet, 1999